Watch RLYB. Know when insiders buy.
One email the day a filing lands. Free.
RLYB
Rallybio Corp
16.62
+0.01 +0.06%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $88.3MP/E 3.4DIV YIELD —FCF YIELD —REV TTM $646K −15.1%NET INCOME $45.6MNET CASH —52W 3.99 – 17.22SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$5.7M | $43.7M | — | 7.53 | $45.9M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $212K | +0.0% | — | −$8.7M | −$8.3M | — | -1.46 | −$8M | — | — | May 13 |
| Q4 2025 · Dec 31derived | $222K | +484.2% | — | −$6.4M | −$5.9M | — | -1.52 | −$4.7M | — | — | Mar 16 |
| Q3 2025 · Sep 30 | $212K | −29.1% | — | −$6.9M | $16M | — | 0.36 | −$6.5M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | $212K | −29.1% | — | −$10.1M | −$9.7M | — | -0.22 | −$8.4M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $212K | — | — | −$9.7M | −$9.4M | — | -1.69 | −$10.2M | — | — | May 13 |
| Q4 2024 · Dec 31derived | $38K | — | — | −$11.6M | −$11M | — | -9.53 | −$9.9M | — | — | Mar 16 |
| Q3 2024 · Sep 30 | $299K | — | — | −$12.1M | −$11.5M | — | -0.26 | −$13.5M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | $299K | — | — | −$17M | −$16.2M | — | -0.37 | −$10.4M | — | — | Aug 7 |
| Q1 2024 · Mar 31 | $0 | — | — | −$19.8M | −$19M | — | -0.47 | −$15.5M | — | — | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$21.1M | −$20.2M | — | -0.49 | −$11.6M | $12K | −$11.7M | Mar 13 |
| Q3 2023 · Sep 30 | $0 | — | — | −$19.4M | −$18.4M | — | -0.45 | −$16.5M | $0 | −$16.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $858K | — | −$33.1M | −$9M | -1046.4% | -1.59 | −$29.8M | — | — | — | — |
| FY2024 · to Dec 31 | $636K | — | −$60.5M | −$57.8M | -9084.1% | -10.61 | −$49.3M | $0 | −$49.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$78.9M | −$74.6M | — | -1.84 | −$60.3M | $12K | −$60.3M | — | — |
| FY2022 · to Dec 31 | — | — | −$67.9M | −$66.7M | — | -2.09 | −$57.3M | $54K | −$57.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$45.6M | −$47M | — | -1.84 | −$45.5M | $333K | −$45.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$25.3M | −$26.4M | — | -1.52 | −$22M | $137K | −$22.2M | — | — |
Every number comes from Rallybio Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.